Graybug Vision, Inc. (NASDAQ:GRAY – Get Rating) saw a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 62,900 shares, an increase of 60.5% from the April 15th total of 39,200 shares. Based on an average daily trading volume, of 53,000 shares, the short-interest ratio is currently 1.2 days. Currently, 0.5% of the company’s stock are short sold.
A number of equities analysts have recently commented on the stock. Wedbush restated a “neutral” rating and set a $3.00 price objective on shares of Graybug Vision in a research note on Thursday, March 31st. Cantor Fitzgerald cut their target price on shares of Graybug Vision from $4.00 to $2.50 in a research note on Wednesday. Finally, Zacks Investment Research upgraded shares of Graybug Vision from a “sell” rating to a “hold” rating in a research note on Friday. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $3.56.
A number of institutional investors have recently added to or reduced their stakes in GRAY. Renaissance Technologies LLC raised its holdings in Graybug Vision by 221.3% in the 1st quarter. Renaissance Technologies LLC now owns 35,341 shares of the company’s stock valued at $43,000 after acquiring an additional 24,341 shares during the period. State Street Corp increased its holdings in shares of Graybug Vision by 70.7% during the fourth quarter. State Street Corp now owns 35,073 shares of the company’s stock worth $64,000 after purchasing an additional 14,525 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Graybug Vision during the first quarter worth approximately $125,000. Millennium Management LLC bought a new position in shares of Graybug Vision during the second quarter worth approximately $126,000. Finally, GSA Capital Partners LLP bought a new position in shares of Graybug Vision during the fourth quarter worth approximately $158,000. 52.88% of the stock is currently owned by hedge funds and other institutional investors.
Graybug Vision (NASDAQ:GRAY – Get Rating) last released its quarterly earnings results on Thursday, March 10th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.05). Equities analysts anticipate that Graybug Vision will post -1.71 earnings per share for the current year.
Graybug Vision Company Profile (Get Rating)
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
- Get a free copy of the StockNews.com research report on Graybug Vision (GRAY)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.